Yu Jiang1,2,3,4,5, Zixuan Su1,2,3,4,5, Caichen Li1,2,3,4, Jianxing He6,7,8,9,10, Wenhua Liang11,12,13,14,15, Runchen Wang1,2,3,4,5, Yaokai Wen1,2,3,4,5, Hengrui Liang1,2,3,4. 1. Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. 2. State Key Laboratory of Respiratory Disease, Guangzhou, 510120, China. 3. National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China. 4. Guangzhou Institute of Respiratory Health, Guangzhou, 510120, China. 5. Nanshan School, Guangzhou Medical University, Jingxiu Road, Panyu District, Guangzhou, 511436, China. 6. Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. drjianxing.he@gmail.com. 7. State Key Laboratory of Respiratory Disease, Guangzhou, 510120, China. drjianxing.he@gmail.com. 8. National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China. drjianxing.he@gmail.com. 9. Guangzhou Institute of Respiratory Health, Guangzhou, 510120, China. drjianxing.he@gmail.com. 10. China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China. drjianxing.he@gmail.com. 11. Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. liangwh1987@163.com. 12. State Key Laboratory of Respiratory Disease, Guangzhou, 510120, China. liangwh1987@163.com. 13. National Clinical Research Center for Respiratory Disease, Guangzhou, 510120, China. liangwh1987@163.com. 14. Guangzhou Institute of Respiratory Health, Guangzhou, 510120, China. liangwh1987@163.com. 15. China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China. liangwh1987@163.com.
Abstract
PURPOSE: We aimed to elucidate the associations between aspirin use with risk of lung cancer, by conducting a meta-analysis and Mendelian randomization (MR) analyses from published Genome-Wide Association Studies (GWAS). METHODS: Cohort studies, nested case-control studies, and randomized controlled trials (RCTs) investigating the impact of aspirin exposure and lung cancer incidence were included. Relative risk (RR) and its 95% confidence interval (CI) were evaluated in eligible studies. Subgroup analyses regarding gender, pathologic subtypes and smoking status were also executed. MR analyses were conducted using summary statistics obtained from two large consortia [Neale Lab and International Lung Cancer Consortium (ILCCO)] to assess the possible causal relationship of aspirin on lung cancer incidence. RESULTS: Sixteen eligible studies involving 1,522,687 patients were included. The combined RR of aspirin use for the incidence of lung cancer was 0.95 (95% confidence interval (CI) 0.91-0.98). In subgroup meta-analyses, a significant protective effect was observed in squamous cell lung cancer (RR = 0.80; 95% CI 0.65-0.98). In terms of gender, the chemopreventive value was only observed among men (RR = 0.87; 95% CI 0.77-0.97). The MR risk analysis suggested a causal effect of aspirin on lung cancer incidence, with evidence of a decreased risk for overall lung cancer (OR = 0.042; 95% CI 0.003-0.564) and squamous cell lung cancer (OR = 0.002; 95% CI 1.21 × 10-5-0.301). CONCLUSION: Our study provided evidence for a causal protective effect of aspirin on the risk of lung cancer incidence among men, particularly on the squamous cell lung cancer risk.
PURPOSE: We aimed to elucidate the associations between aspirin use with risk of lung cancer, by conducting a meta-analysis and Mendelian randomization (MR) analyses from published Genome-Wide Association Studies (GWAS). METHODS: Cohort studies, nested case-control studies, and randomized controlled trials (RCTs) investigating the impact of aspirin exposure and lung cancer incidence were included. Relative risk (RR) and its 95% confidence interval (CI) were evaluated in eligible studies. Subgroup analyses regarding gender, pathologic subtypes and smoking status were also executed. MR analyses were conducted using summary statistics obtained from two large consortia [Neale Lab and International Lung Cancer Consortium (ILCCO)] to assess the possible causal relationship of aspirin on lung cancer incidence. RESULTS: Sixteen eligible studies involving 1,522,687 patients were included. The combined RR of aspirin use for the incidence of lung cancer was 0.95 (95% confidence interval (CI) 0.91-0.98). In subgroup meta-analyses, a significant protective effect was observed in squamous cell lung cancer (RR = 0.80; 95% CI 0.65-0.98). In terms of gender, the chemopreventive value was only observed among men (RR = 0.87; 95% CI 0.77-0.97). The MR risk analysis suggested a causal effect of aspirin on lung cancer incidence, with evidence of a decreased risk for overall lung cancer (OR = 0.042; 95% CI 0.003-0.564) and squamous cell lung cancer (OR = 0.002; 95% CI 1.21 × 10-5-0.301). CONCLUSION: Our study provided evidence for a causal protective effect of aspirin on the risk of lung cancer incidence among men, particularly on the squamous cell lung cancer risk.
Authors: Yin Cao; Reiko Nishihara; Kana Wu; Molin Wang; Shuji Ogino; Walter C Willett; Donna Spiegelman; Charles S Fuchs; Edward L Giovannucci; Andrew T Chan Journal: JAMA Oncol Date: 2016-06-01 Impact factor: 31.777
Authors: Kelly E Lloyd; Louise H Hall; Natalie King; Rachael J Thorneloe; Rocio Rodriguez-Lopez; Lucy Ziegler; David G Taylor; Mairead MacKenzie; Samuel G Smith Journal: Prev Med Date: 2021-11-09 Impact factor: 4.018